Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year

被引：8

作者：

Galluzzo, Marco ^{[1
,2
]}

Talamonti, Marina ^{[1
,2
]}

Bernardini, Nicoletta ^{[3
]}

Chiricozzi, Andrea ^{[4
,5
]}

De Simone, Clara ^{[4
,5
]}

Bonifati, Claudio ^{[6
]}

Bruni, Pierluigi ^{[7
]}

Diotallevi, Federico ^{[8
]}

Esposito, Maria ^{[9
]}

Graceffa, Dario ^{[6
]}

Hansel, Katharina ^{[10
]}

Loconsole, Francesco ^{[11
]}

Moretta, Gaia ^{[12
]}

Mugheddu, Cristina ^{[13
]}

Papini, Manuela ^{[7
]}

Richetta, Antonio ^{[14
]}

Skroza, Nevena ^{[3
]}

Atzori, Laura ^{[13
]}

Fargnoli, Maria Concetta ^{[9
]}

Persechino, Severino ^{[15
]}

Offidani, Annamaria ^{[8
]}

Stingeni, Luca ^{[10
]}

Peris, Ketty ^{[4
,5
]}

Potenza, Concetta ^{[3
]}

Bianchi, Luca ^{[1
,2
]}

机构：

[1] Univ Roma Tor Vergata, Dept Syst Med, Rome, Italy

[2] Fdn Policlin Tor Vergata, Dermatol Unit, Rome, Italy

[3] Sapienza Univ Rome Polo Pontino, Dermatol, Rome, Italy

[4] Fdn Policlin Univ A Gemelli IRCCS, Dipartimento Med & Chirurg Traslaz, UOC Dermatol, Rome, Italy

[5] Univ Cattolica Sacro Cuore, Dipartimento Med & Chirurg Traslaz, Dermatol, Rome, Italy

[6] San Gallicano Dermatol Inst IRCCS, Dermatol Unit, Rome, Italy

[7] Univ Perugia, Terni Hosp, Dermatol, Terni, Italy

[8] Polytech Marche Univ, Dept Clin & Mol Sci, Dermatol Unit, Ancona, Italy

[9] Univ Aquila, Dermatol Biotechnol & Appl Clin Sci, Laquila, Italy

[10] Univ Perugia, Dept Dermatol & Venereol, Dermatol Sect, Perugia, Italy

[11] Univ Hosp Policlin Univ Bari, Dermatol Clin, Bari, Italy

[12] IDI IRCCS, Dermatol Dept, Rome, Italy

[13] Univ Cagliari, Dermatol, Cagliari, Italy

[14] Sapienza Univ Rome Umberto I Hosp, Dermatol, Rome, Italy

[15] Sapienza Univ Rome, Dept Neurosci Salute Mentale & Organi Senso NESMO, Rome, Italy

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2022年 / 22卷 / 12期

关键词：

Guselkumab; efficacy; plaque psoriasis; treatment; real-world; PRACTICAL EXPERIENCE; SAFETY; USTEKINUMAB; ADALIMUMAB; THERAPIES; EFFICACY; UK;

D O I：

10.1080/14712598.2022.2090835

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Background Real-world data on guselkumab, especially at times >6 months, are limited. Research design and methods We performed a longitudinal, retrospective analysis on 307 patients with moderate-severe chronic plaque psoriasis (Psoriasis Area Severity Index [PASI] >10) treated with guselkumab for up to 12 months. Main outcome measures PASI 75, PASI 90, and PASI 100 were assessed at baseline and at 4, 12, 20, 28, 36, 44, and 52 weeks. Results At 12 weeks, PASI 75, PASI 90, and PASI 100 were achieved in 56.4%, 33.6%, and 24.1% of patients, respectively. At 52 weeks, PASI 75, PASI 90, and PASI 100 were achieved in 82.7%, 68.7%, and 51.1% of patients, respectively. Patients without comorbidities and those naive to previous biological therapy had better responses. The mean Dermatology Life Quality Index score decreased from 14.0 at baseline to 3.1 at 12 weeks and 1.6 at 6 months, which was maintained at later times. Similar improvements were seen in pruritus visual analog scale. Conclusions Guselkumab maintains its efficacy for up to 12 months among responders in a real-world cohort of patients with moderate-severe plaque psoriasis, confirming data from prior real-world studies with smaller cohorts and shorter duration of follow-up.

引用

页码：1585 / 1592

页数：8

共 33 条

[1] Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies [J].

Armstrong, April W. ;

Reich, Kristian ;

Foley, Peter ;

Han, Chenglong ;

Song, Michael ;

Shen, Yaung-Kaung ;

You, Yin ;

Papp, Kim A. .

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2019, 20 (01) :155-164

[2] Guselkumab for the treatment of psoriasis: a 60-week real-life multicenter retrospective experience [J].

Bardazzi, Federico ;

Viviani, Filippo ;

Merli, Yuri ;

Di Lernia, Vito ;

Peccerillo, Francesca ;

Conti, Andrea ;

Lasagni, Claudia ;

Tabanelli, Michela ;

D'Adamio, Simone ;

Di Nuzzo, Sergio ;

Cortellazzi, Chiara ;

Filippi, Federica .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (12) :1561-1566

[3] Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis [J].

Blauvelt, Andrew ;

Tsai, Tsen-Fang ;

Langley, Richard G. ;

Miller, Megan ;

Shen, Yaung-Kaung ;

You, Yin ;

Yang, Ya-Wen ;

Papp, Kim A. ;

Puig, Luis .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 86 (04) :827-834

[4] Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatore-controlled VOYAGE 1 trial [J].

Blauvelt, Andrew ;

Papp, Kim A. ;

Griffiths, Christopher E. M. ;

Randazzo, Bruce ;

Wasfi, Yasmine ;

Shen, Yaung-Kaung ;

Li, Shu ;

Kimball, Alexa B. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (03) :405-417

[5] Effectiveness of IL-23 Inhibitor Guselkumab in Real-World Chinese Patients with Psoriasis During a 20-Week Period [J].

Chan, Yung ;

Tong, Bik Sai Bessie ;

Ngan, Pui Yan ;

Au, Chi Sum .

PSORIASIS-TARGETS AND THERAPY, 2021, 11 :53-58

[6] Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group [J].

del Alcazar, Elena ;

Lopez-Ferrer, Anna ;

Martinez-Domenech, Alvaro ;

Ruiz-Villaverde, Ricardo ;

Llamas-Velasco, Ma. del Mar ;

Rocamora, Vicenc ;

Julia, Marc ;

Notario, Jaime ;

Fernandez-Freire, Lourdes Rodriguez ;

Sahuquillo-Torralba, Antonio ;

Vidal, David ;

Rivera, Raquel ;

Carretero, Gregorio ;

Mateu, Almudena ;

de la Cueva, Pablo ;

Carrascosa, Jose Manuel .

DERMATOLOGIC THERAPY, 2022, 35 (02)

[7] Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study [J].

Galluzzo, Marco ;

Tofani, Lorenzo ;

Lombardo, Paolo ;

Petruzzellis, Alessandra ;

Silvaggio, Dionisio ;

Egan, Colin Gerard ;

Bianchi, Luca ;

Talamonti, Marina .

JOURNAL OF CLINICAL MEDICINE, 2020, 9 (07) :1-16

[8] Real-world effectiveness of guselkumab in patients with psoriasis: Health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial [J].

Gerdes, Sascha ;

Braeu, Beate ;

Hoffmann, Matthias ;

Korge, Bernhard ;

Mortazawi, Dariusch ;

Wiemers, Franca ;

Wegner, Sven ;

Personke, Yvonne ;

Gomez, Mario ;

Sticherling, Michael .

JOURNAL OF DERMATOLOGY, 2021, 48 (12) :1854-1862

[9] Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis [J].

Gisondi, P. ;

Altomare, G. ;

Ayala, F. ;

Bardazzi, F. ;

Bianchi, L. ;

Chiricozzi, A. ;

Costanzo, A. ;

Conti, A. ;

Dapavo, P. ;

De Simone, C. ;

Foti, C. ;

Naldi, L. ;

Offidani, A. ;

Parodi, A. ;

Piaserico, S. ;

Prignano, F. ;

Rongioletti, F. ;

Stingeni, L. ;

Talamonti, M. ;

Girolomoni, G. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (05) :774-790

[10] Treatment Approaches to Moderate to Severe Psoriasis [J].

Gisondi, Paolo ;

Del Giglio, Micol ;

Girolomoni, Giampiero .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (11)

← 1 2 3 4 →